Ptc Therapeutics Inc (PTCT) 70.48 $PTCT
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
at The Street - Thu Apr 23, 9:01AM CDT
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 8:13AM CDT
PBR.A: 8.91 (+0.23), SKX: 89.66 (+2.79), SNE: 31.34 (+0.62), NVGN: 6.54 (-0.01), VLTC: 11.54 (+0.50), PBR: 9.99 (+0.59), DNKN: 54.03 (+2.52), NJ: 18.57 (+0.12), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), ERIC: 11.41 (-0.17), TXN: 54.73 (+0.01), PHM: 20.12 (+0.15), PTCT: 70.48 (-0.88), DPZ: 113.96 (+4.73), MOBL: 6.97 (-0.14)
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire - Thu Apr 23, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:
PTCT: 70.48 (-0.88), DB: 34.26 (+0.11)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results
PR Newswire - Mon Apr 20, 7:02AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2015 financial results on Monday, May 4, 2015 at 4:30 p.m. (ET) after the closing of the market.
PTCT: 70.48 (-0.88)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Fri Apr 10, 3:31PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 7, 2015 it approved non-statutory stock options to purchase an aggregate of 264,200 shares of its common stock to 25 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 70.48 (-0.88)
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
PR Newswire - Wed Apr 08, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organizational build out and launch of Translarna in the US, Canada and Latin America.
PTCT: 70.48 (-0.88)
Sarepta's Long Road Ahead
Kanak Kanti De - at Seeking Alpha - Mon Apr 06, 3:29PM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
PTC Therapeutics (PTCT) Is Weak On High Volume Today
at The Street - Wed Mar 25, 9:03AM CDT
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate
PTCT: 70.48 (-0.88)
InsiderInsights.com Daily Round Up 3/23/15: ANF, OPK, HEES, MLNK
InsiderInsights - at Seeking Alpha - Tue Mar 24, 3:11PM CDT
MDGN: 8.97 (-0.15), FMBH: 20.00 (-0.28), DEI: 29.41 (+0.09), GARS: 15.03 (unch), MLNK: 3.66 (-0.05), GOOG: 565.06 (+18.06), VLO: 60.05 (+0.82), PN: 14.13 (+0.44), ESPR: 104.60 (-4.29), OPK: 14.83 (+0.17), ANF: 22.86 (-0.03), RSPP: 28.44 (-0.25), PTCT: 70.48 (-0.88), DYN: 33.53 (+0.86), ANAC: 64.49 (-2.10), GOOGL: 573.66 (+16.20), HEES: 24.49 (-1.09), EME: 46.46 (-0.12), SAEX: 3.30 (-0.11), ALCO: 47.11 (-0.65)
PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company
at The Street - Tue Mar 24, 9:39AM CDT
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.
PTCT: 70.48 (-0.88)
PTC Therapeutics and University of Pennsylvania Collaborate on Orphan Disease Research
PR Newswire - Thu Mar 19, 7:00AM CDT
PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania focused on translational research for discovering and developing new treatments for orphan disorders. The partnership reflects both parties' commitment to developing treatments and improving the lives of those who suffer from rare diseases.
PTCT: 70.48 (-0.88)
Insider Trading Alert - NKSH, PTCT And NNN Traded By Insiders
at The Street - Mon Mar 16, 10:00AM CDT
Stocks with insider trader activity include NKSH, PTCT and NNN
NKSH: 29.80 (+0.29), NNN: 41.04 (-0.13), PTCT: 70.48 (-0.88)
New Jersey Rare Disease Alliance Event Supports Rare Disease Community at State House on March 16
Business Wire - Thu Mar 12, 11:31AM CDT
The New Jersey Rare Disease Alliance, a newly formed organization dedicated to improving the lives of the 800,000 rare disease patients in NJ, is hosting their first event at the New Jersey State House on March 16 in Room 14 of the Annex Building. Supported by BioNJ and NORD (National Organization for Rare Disorders), the event coincides with the Rare Disease Day and Month events planned all over the world.
PTCT: 70.48 (-0.88)
Insider Trading Alert - GNMK, PTCT And ALG Traded By Insiders
at The Street - Thu Mar 12, 10:45AM CDT
Stocks with insider trader activity include GNMK, PTCT and ALG
GNMK: 10.69 (-0.24), PTCT: 70.48 (-0.88), ALG: 63.46 (+0.03)
InsiderInsights.com Daily Round Up 3/11/15: ETP, TEP, BYBK, GEF
InsiderInsights - at Seeking Alpha - Thu Mar 12, 8:23AM CDT
TAX: 28.73 (+0.42), NOC: 161.78 (-1.05), SLXP: 172.96 (+0.15), BYBK: 5.24 (+0.04), GEF: 39.55 (+0.27), SEM: 15.52 (+0.22), GWR: 95.31 (-1.15), AMH: 17.20 (+0.10), AMRC: 7.18 (-0.12), TEP: 49.32 (-0.27), PODD: 30.72 (+0.11), ETP: 55.67 (+0.50), SGEN: 37.14 (-0.36), BWINB: 23.08 (+0.05), COMM: 28.22 (-1.08), SUNE: 26.61 (-0.89), CHGG: 8.06 (-0.02), NCLH: 51.41 (-0.25), PTCT: 70.48 (-0.88), EIGI: 22.80 (-0.23)
Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now
at The Street - Thu Mar 05, 7:58AM CST
Biotechnology and health care in general are some of the hottest areas for investment these days.
PCYC: 256.59 (-0.51), MDT: 77.61 (-0.89), CAH: 91.38 (-0.12), CYH: 55.34 (+0.12), CS: 26.16 (-0.48), PTCT: 70.48 (-0.88), ILMN: 189.59 (-3.01), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), AET: 108.82 (-0.08), CELG: 118.71 (+2.62)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 133.20 (-2.62), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), AMGN: 167.91 (-1.26), DYAX: 27.44 (-0.85), JNJ: 101.08 (+0.62), ESPR: 104.60 (-4.29), KITE: 60.58 (-0.35), RCPT: 169.88 (-1.26), PTCT: 70.48 (-0.88), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01)
3 Biotech Stocks That Are Soaring Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 9:58AM CST
Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech...
PCYC: 256.59 (-0.51), TSRO: 64.00 (-0.65), PTCT: 70.48 (-0.88)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Santhera -- A Duchenne Drug With Positive Study Results That Few Know About
at The Street - Thu Apr 23, 9:01AM CDT
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 8:13AM CDT
PBR.A: 8.91 (+0.23), SKX: 89.66 (+2.79), SNE: 31.34 (+0.62), NVGN: 6.54 (-0.01), VLTC: 11.54 (+0.50), PBR: 9.99 (+0.59), DNKN: 54.03 (+2.52), NJ: 18.57 (+0.12), LOOK: 1.97 (+0.37), ARRS: 35.76 (-1.54), ERIC: 11.41 (-0.17), TXN: 54.73 (+0.01), PHM: 20.12 (+0.15), PTCT: 70.48 (-0.88), DPZ: 113.96 (+4.73), MOBL: 6.97 (-0.14)
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire - Thu Apr 23, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:
PTCT: 70.48 (-0.88), DB: 34.26 (+0.11)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2015 Financial Results
PR Newswire - Mon Apr 20, 7:02AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2015 financial results on Monday, May 4, 2015 at 4:30 p.m. (ET) after the closing of the market.
PTCT: 70.48 (-0.88)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Fri Apr 10, 3:31PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 7, 2015 it approved non-statutory stock options to purchase an aggregate of 264,200 shares of its common stock to 25 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 70.48 (-0.88)
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
PR Newswire - Wed Apr 08, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organizational build out and launch of Translarna in the US, Canada and Latin America.
PTCT: 70.48 (-0.88)
Sarepta's Long Road Ahead
Kanak Kanti De - at Seeking Alpha - Mon Apr 06, 3:29PM CDT
BMRN: 120.28 (-2.67), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88)
PTC Therapeutics (PTCT) Is Weak On High Volume Today
at The Street - Wed Mar 25, 9:03AM CDT
Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate
PTCT: 70.48 (-0.88)
InsiderInsights.com Daily Round Up 3/23/15: ANF, OPK, HEES, MLNK
InsiderInsights - at Seeking Alpha - Tue Mar 24, 3:11PM CDT
MDGN: 8.97 (-0.15), FMBH: 20.00 (-0.28), DEI: 29.41 (+0.09), GARS: 15.03 (unch), MLNK: 3.66 (-0.05), GOOG: 565.06 (+18.06), VLO: 60.05 (+0.82), PN: 14.13 (+0.44), ESPR: 104.60 (-4.29), OPK: 14.83 (+0.17), ANF: 22.86 (-0.03), RSPP: 28.44 (-0.25), PTCT: 70.48 (-0.88), DYN: 33.53 (+0.86), ANAC: 64.49 (-2.10), GOOGL: 573.66 (+16.20), HEES: 24.49 (-1.09), EME: 46.46 (-0.12), SAEX: 3.30 (-0.11), ALCO: 47.11 (-0.65)
PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company
at The Street - Tue Mar 24, 9:39AM CDT
Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.
PTCT: 70.48 (-0.88)
PTC Therapeutics and University of Pennsylvania Collaborate on Orphan Disease Research
PR Newswire - Thu Mar 19, 7:00AM CDT
PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania focused on translational research for discovering and developing new treatments for orphan disorders. The partnership reflects both parties' commitment to developing treatments and improving the lives of those who suffer from rare diseases.
PTCT: 70.48 (-0.88)
Insider Trading Alert - NKSH, PTCT And NNN Traded By Insiders
at The Street - Mon Mar 16, 10:00AM CDT
Stocks with insider trader activity include NKSH, PTCT and NNN
NKSH: 29.80 (+0.29), NNN: 41.04 (-0.13), PTCT: 70.48 (-0.88)
New Jersey Rare Disease Alliance Event Supports Rare Disease Community at State House on March 16
Business Wire - Thu Mar 12, 11:31AM CDT
The New Jersey Rare Disease Alliance, a newly formed organization dedicated to improving the lives of the 800,000 rare disease patients in NJ, is hosting their first event at the New Jersey State House on March 16 in Room 14 of the Annex Building. Supported by BioNJ and NORD (National Organization for Rare Disorders), the event coincides with the Rare Disease Day and Month events planned all over the world.
PTCT: 70.48 (-0.88)
Insider Trading Alert - GNMK, PTCT And ALG Traded By Insiders
at The Street - Thu Mar 12, 10:45AM CDT
Stocks with insider trader activity include GNMK, PTCT and ALG
GNMK: 10.69 (-0.24), PTCT: 70.48 (-0.88), ALG: 63.46 (+0.03)
InsiderInsights.com Daily Round Up 3/11/15: ETP, TEP, BYBK, GEF
InsiderInsights - at Seeking Alpha - Thu Mar 12, 8:23AM CDT
TAX: 28.73 (+0.42), NOC: 161.78 (-1.05), SLXP: 172.96 (+0.15), BYBK: 5.24 (+0.04), GEF: 39.55 (+0.27), SEM: 15.52 (+0.22), GWR: 95.31 (-1.15), AMH: 17.20 (+0.10), AMRC: 7.18 (-0.12), TEP: 49.32 (-0.27), PODD: 30.72 (+0.11), ETP: 55.67 (+0.50), SGEN: 37.14 (-0.36), BWINB: 23.08 (+0.05), COMM: 28.22 (-1.08), SUNE: 26.61 (-0.89), CHGG: 8.06 (-0.02), NCLH: 51.41 (-0.25), PTCT: 70.48 (-0.88), EIGI: 22.80 (-0.23)
Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now
at The Street - Thu Mar 05, 7:58AM CST
Biotechnology and health care in general are some of the hottest areas for investment these days.
PCYC: 256.59 (-0.51), MDT: 77.61 (-0.89), CAH: 91.38 (-0.12), CYH: 55.34 (+0.12), CS: 26.16 (-0.48), PTCT: 70.48 (-0.88), ILMN: 189.59 (-3.01), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), AET: 108.82 (-0.08), CELG: 118.71 (+2.62)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 133.20 (-2.62), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), AMGN: 167.91 (-1.26), DYAX: 27.44 (-0.85), JNJ: 101.08 (+0.62), ESPR: 104.60 (-4.29), KITE: 60.58 (-0.35), RCPT: 169.88 (-1.26), PTCT: 70.48 (-0.88), ICPT: 283.20 (-2.22), ABBV: 66.07 (+1.82), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01)
3 Biotech Stocks That Are Soaring Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 9:58AM CST
Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech...
PCYC: 256.59 (-0.51), TSRO: 64.00 (-0.65), PTCT: 70.48 (-0.88)
